RxDoctor Payments Data

Samir Zaina, MD

Family Medicine · Paterson, NJNPI 1699906354

Payments from drug & device makers

$1,543in general payments, 2019–2025

Across 27 payments — averaging $57.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$663
  • AstraZeneca$426
  • GSK$177
  • Madrigal Pharmaceuticals$125
  • Lilly USA, LLC$56
  • Amarin Pharma, Inc.$47
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$1,52999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,543 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$70,765
Medicare patients
136
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin197$181,758
JanumetSitagliptin Phos/Metformin Hcl176$155,418
OzempicSemaglutide99$110,555
JanuviaSitagliptin Phosphate115$98,949
EliquisApixaban81$68,630
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$65,605
EntrestoSacubitril/Valsartan30$33,578
CreonLipase/Protease/Amylase16$28,795
LinzessLinaclotide45$28,259
FarxigaDapagliflozin Propanediol25$24,883
Fluticasone-SalmeterolFluticasone Propion/Salmeterol129$19,843
VascepaIcosapent Ethyl39$19,760
BrilintaTicagrelor24$19,549
Diclofenac Sodium99$19,284
JentaduetoLinagliptin/Metformin Hcl22$18,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto, Synjardy$15$206,890230 claims
GSKTrelegy Ellipta, Breo Ellipta$177$76,256111 claims
PfizerEliquis$16$68,63081 claims
AbbVieCreon, Linzess$663$57,05461 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort$426$55,05373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →